Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of a Provincial Law to Improve Epinephrine Use for Anaphylaxis in Schools in Alberta, Canada: A Pre-Post Study.

International archives of allergy and immunology·2026
Same author

Why physicians underuse patient-reported outcomes in atopic dermatitis and chronic urticaria - Insights from the UCARE/ADCARE PROMUSE study.

The World Allergy Organization journal·2026
Same author

Eosinophilic Esophagitis following Oral Immunotherapy: A Systematic Review and Meta-Analysis.

International archives of allergy and immunology·2026
Same author

Food Protein-Induced Enterocolitis Syndrome among Canadian Children Living in Montreal.

International archives of allergy and immunology·2026
Same author

Seasonal Peaks and Climatic Predictors of Chronic Urticaria: A Global Google Trends Analysis.

Journal of cutaneous medicine and surgery·2026
Same author

Diagnosis and Management of Comorbid Autoimmune Disorders in Children with Chronic Spontaneous Urticaria.

Journal of inflammation research·2026
Same journal

Childhood Infectious Encephalitis: An Overview of Clinical Features, Investigations, Treatment, and Recent Patents.

Recent patents on inflammation & allergy drug discovery·2020
Same journal

Nummular Eczema: An Updated Review.

Recent patents on inflammation & allergy drug discovery·2020
Same journal

Childhood Alopecia Areata: An Overview of Treatment and Recent Patents.

Recent patents on inflammation & allergy drug discovery·2020
Same journal

Human Ascariasis: An Updated Review.

Recent patents on inflammation & allergy drug discovery·2020
Same journal

Scenario of the Treatment of Arthritis with Natural Products.

Recent patents on inflammation & allergy drug discovery·2020
Same journal

Acute Myocarditis in Children: An Overview of Treatment and Recent Patents.

Recent patents on inflammation & allergy drug discovery·2020
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Omalizumab: not only for asthma.

Moshe Ben-Shoshan1

  • 1Division of Pediatric Allergy and Clinical Immunology, McGill University Health Center, Montreal, Quebec, Canada. daliamoshebs@gmail.com

Recent Patents on Inflammation & Allergy Drug Discovery
|December 17, 2008
PubMed
Summary
This summary is machine-generated.

Omalizumab, a monoclonal antibody, effectively treats severe allergic asthma. Emerging research indicates its potential for other IgE-mediated conditions and immunotherapy enhancement, warranting further investigation.

More Related Videos

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

Related Experiment Videos

Last Updated: Jun 27, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

Area of Science:

  • Immunology
  • Allergology
  • Pharmacology

Background:

  • Omalizumab is a humanized monoclonal antibody.
  • It is approved for moderate-to-severe persistent allergic asthma uncontrolled by high-dose inhaled corticosteroids.

Purpose of the Study:

  • To review the efficacy of omalizumab beyond asthma treatment.
  • To explore its role in other IgE-mediated diseases and immunotherapy.
  • To identify future research needs and guide clinical practice.

Main Methods:

  • Literature review of studies on omalizumab.
  • Analysis of clinical data and trial outcomes.
  • Discussion of safety profiles and patent landscape.

Main Results:

  • Omalizumab shows promise in treating urticaria, angioedema, atopic dermatitis, allergic rhinitis, nasal polyposis, and ocular allergies.
  • Combining omalizumab with immunotherapy appears highly beneficial.
  • Potential risks include anaphylaxis and association with Churg-Strauss syndrome.

Conclusions:

  • Omalizumab has broader therapeutic potential than initially recognized.
  • Further research is needed to establish its role in new indications and optimize its use.
  • Close patient monitoring is essential due to potential adverse events.